Anacetrapib

Drug / Medication

Merck's CETP inhibitor which, despite only moderately lowering LDL, confirmed that CETP inhibition reduces heart attacks by lowering LDL, fitting the CTT meta-regression line.

Mentioned in 2 videos

Videos Mentioning Anacetrapib

255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia

255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia

Peter Attia MD

Merck's CETP inhibitor which, despite only moderately lowering LDL, confirmed that CETP inhibition reduces heart attacks by lowering LDL, fitting the CTT meta-regression line.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

A CETP inhibitor by Merck that showed a small, though not spectacular, cardiovascular benefit in the REVEAL trial, but drug accumulation in adipose tissue stopped further development.